Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment-Reference-Cited by-同舟云学术

Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment

Published:2024-05-08 Issue: Volume: Page:1-5
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Caldarola Giacomo¹²,Pinto Lorenzo Maria¹²,Bellinato Francesco³,Bernardini Nicoletta⁴,Campione Elena⁵⁶,Chiricozzi Andrea¹²^ORCID,Colonna Laura⁷,De Simone Clara¹²,Diluvio Laura⁵⁶,Gisondi Paolo³^ORCID,Matteini Enrico⁵,Tomassetti Eleonora¹²,Tolino Ersilia⁴,Bianchi Luca⁵⁶,Peris Ketty¹²

Affiliation:

1. UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy

2. Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy

3. Department of Medicine, Section of Dermatology, University of Verona, Verona, Italy

4. Dermatology Unit “Daniele Innocenzi” ASL LATINA, Sapienza University of Rome, Rome, Italy

5. UOSD di Dermatologia, Azienda Ospedaliera Universitaria “Policlinico Tor Vergata”, Rome, Italy

6. Dipartimento di Medicina dei Sistemi, Università di Roma, Rome, Italy

7. Dermatology Unit, IDI-IRCCS, Rome, Italy

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2024.2348571

Reference14 articles.

1. Alopecia areata

2. Hair Follicle Immune Privilege Revisited: The Key to Alopecia Areata Management

3. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition

4. JAK Inhibitors for Treatment of Alopecia Areata

5. FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis [Internet]. USA: LLC; 2018 Jun 1 [cited 2023 Dec 1]. Available from: https://investor.lilly.com/news-releases/news-release-details/fda-approves-olumiantr-baricitinib-2-mg-tablets-treatment-adults